Compare GSK plc (GSK) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tyson Foods, Inc. — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Tyson Foods, Inc. trades at $53.43 (market cap $18.41B). The key difference: GSK plc is far larger — about 5× Tyson Foods, Inc.'s market cap, and GSK plc is more actively traded (7,730,529 versus 3,757,599). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Tyson Foods, Inc. for 76 Days on average.
| GSK | TSN | |
|---|---|---|
Market Cap | $91.88B | $18.41B |
Volume | 7,730,529 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $68.75 |
52-Week Low | $43.24 | $50.47 |
Typical Hold Time | 93 Days | 76 Days |
Enterprise Value | $111.88B | $25.68B |
Dividend Yield | 3.9% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Tyson Foods (TSN) trades at $52.34, up 1.24% on the day, with a bullish technical signal but mixed earnings history including a recent Q4 2025 miss. Valuation ratios like P/S of 0.33 appear attractive, but thin net margins of 1.03% and ongoing cash flow challenges highlight operational pressures. Recent news includes a lowered fiscal 2026 outlook and a securities investigation, adding uncertainty despite insider buying and institutional interest.
The stock offers a potential 25% upside to the consensus price target of $65.40, supported by a majority analyst buy rating. However, risks are elevated from beef segment losses, negative cash flows, and legal scrutiny. Investor sentiment is cautious amid guidance cuts, making earnings execution critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
